Ezutromid Shows Potential in DMD | Medpage Today: "LOS ANGELES -- The investigative utrophin modulator ezutromid showed promise in treating Duchenne muscular dystrophy, according to a interim analysis of an open-label, phase II clinical trial.
Ezutromid appeared to have significantly deceased inflammation in the calf muscle of Duchenne patients after 24 weeks, reported Anne Heatherington, PhD, of Summit Therapeutics in Oxford, England, and colleagues at the American Academy of Neurology annual meeting."
'via Blog this'
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment